What do LiveSpo NAVAX results show about pneumonia treatment duration?

Question

Accepted Answer

LiveSpo NAVAX Shortened Pneumonia Treatment Duration in Children

Clinical trial results for LiveSpo NAVAX, a probiotic nasal spray, indicate a reduction in the treatment duration for pneumonia in children experiencing co-infections with RSV and bacteria. Specifically, the average treatment period was shortened by one day.
Reduced Antibiotic Use

The implementation of LiveSpo NAVAX in the treatment regimen for these children also demonstrated a significant decrease in the reliance on antibiotics. The studies showed a reduction in antibiotic consumption by nearly 15%.
Nasal Microbiota Improvement

Beyond reducing treatment time and antibiotic use, LiveSpo NAVAX positively impacted the nasal microbiota of the pediatric patients. The probiotic intervention was found to improve the microbial balance by decreasing the presence of pathogenic bacteria, including Streptococcus pneumoniae and Haemophilus influenzae.

Reading history

Hide →

This history is cleared when the page is closed.

What do LiveSpo NAVAX results show about pneumonia treatment duration?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends